06.04.25 -- Tariffs On Toys … And API? Biopharma As The Next Battleground

Explore two studies where lung cancer therapies were delivered to the lung by dry powder inhaler in a rat model and evaluated for efficacy, confirming local delivery is a promising route to treat lung cancer.

When developing a nasal delivery program, a partner with experience in development and manufacturing techniques who can see a program through small-scale clinical to commercial supply is crucial.

Unlocking the potential of oral protein therapeutics requires innovative formulation and manufacturing strategies to overcome stability, absorption, and bioavailability challenges.

Employing multiple AI models to analyze public sentiment of generic drugs minimizes bias and enhances reliability. This makes AI a proactive tool for pharmaceutical quality assurance.

Consider innovative solutions for improving the solubility and bioavailability of poorly soluble compounds in solid oral dosage forms to enhance drug delivery and therapeutic effectiveness.

In this session, Chief Scientific Officer Dr. Andy Lewis delves into the key drivers shaping peptide drug development and explores innovative delivery options to enhance therapeutic outcomes.

A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.

Join Outsourced Pharma Live on June 11th at 2pm ET for a virtual panel discussion on the specific challenges of biologics development that must drive CDMOs to embrace more flexible approaches. Registration is free thanks to the support of Curia.

From first in human (FIH) through to phase 3 clinical supplies manufacturing at our MHRA-approved and Home Office-approved (I-IV) GMP facility, Trent Gateway.

Gain a strategic edge through customized solutions, reliable metrics, and a clear pathway to successful downstream testing, ensuring your therapeutics reach patients faster.

Learn how our chemical manufacturing facilities are equipped to support a wide range of projects with on-site pilot plants and large-scale commercial capabilities for manufacturing high-quality APIs.

Caddy Hobbs, Ph.D., takes an in-depth look at our analytical services, which support the full drug development lifecycle — from early development through to commercial manufacturing.